Understanding the Genetic
Architecture of Parkinson's Disease

The Global Parkinson’s Genetics Program (GP2) is an ambitious five-year program to genotype >150,000 volunteers around the world to further understand the genetic architecture of Parkinson’s disease (PD). There is still much to learn about genetic risk factors and the path to further understanding requires working collaboratively and openly sharing data, processes, and results.

Monogenic Hub 

Submit data, access statistics, and learn about opportunities to contribute to the investigation of people with Parkinson’s who potentially have a monogenic cause.

Submit a Cohort

Collaborate with us and submit a cohort to GP2. Fill out our form to get started.
  

GP2 Updates

Check out the latest news about GP2.

  • Black and African American Connections to PD

    GP2 launched BLAAC PD: Black and African American Connections to Parkinson’s Disease, as part of our commitment to increase representation in research and care within communities.

  • GP2 Opportunities

    Development is an important component of our program; our focus is to provide training and other funding opportunities for the next generation of Parkinson’s disease researchers around the world. GP2 will offer these opportunities to the entire neurodegeneration community through the course of the program.

  • Introduction to GP2

    In the first GP2 blog post, Andrew Singleton, NIH Distinguished Investigator and GP2 Lead, introduces the program's aims, values and vision.

Latest Blog Posts

Read the latest blogs from GP2’s scientists and collaborators.

  • What is Compliance and Why is it Important?

    By GP2 Operations and Compliance Working Group | Research Operations |

    Members of the GP2 Operations and Compliance working group provide an overview of what compliance is and why it is important in GP2.

  • Understanding GWAS

    By GP2 Complex Disease Data Analysis Working Group | Complex disease genetics |

    Members of the GP2 Complex Disease Data Analysis working group provide an overview of Genome-Wide Association Studies (GWAS), including statistical formulae, workflows, and examples from the most recent Parkinson’s disease GWAS.

  • Parkinson’s Disease Genetics: Cause, Risk, or Protection?

    By Christine Klein | Monogenic disease genetics |

    Christine Klein leads the GP2 Monogenic Hub. In this post Christine shares how her interest in Parkinson’s disease genetics was sparked, which genes have been discovered so far, and the questions which are still to be answered.

Working Groups

Find out about GP2’s working groups and their recently accomplished milestones.